Translations:Anti-obesity medication/8/en: Difference between revisions

Latest revision as of 18:16, 7 March 2024

Information about message (contribute)

This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.

Message definition (Anti-obesity medication)

===Both===
*[[Amylin]] analogues can both reduce energy intake and increase expenditure and can usefully be combined with [[leptin]] analogues for synergistic effect. The [[dual amylin and calcitonin receptor agonist]] [[cagrilintide]], [[cagrilintide/semaglutide|in combination with semaglutide]], was more effective than semaglutide alone in promoting weight loss in clinical trials.
*[[Glucagon receptor agonist]]s both reduce energy intake and increase energy expenditure in humans. They can cause hyperglycemia so it is recommended to combine them with a hypoglycemic drug, such as a GLP-1 or GIP receptor agonist.

Both

Amylin analogues can both reduce energy intake and increase expenditure and can usefully be combined with leptin analogues for synergistic effect. The dual amylin and calcitonin receptor agonist cagrilintide, in combination with semaglutide, was more effective than semaglutide alone in promoting weight loss in clinical trials.
Glucagon receptor agonists both reduce energy intake and increase energy expenditure in humans. They can cause hyperglycemia so it is recommended to combine them with a hypoglycemic drug, such as a GLP-1 or GIP receptor agonist.

Translations:Anti-obesity medication/8/en: Difference between revisions

Latest revision as of 18:16, 7 March 2024

Both

Navigation menu

Search